公开(公告)号：US11766437B2

公开(公告)日：2023-09-26

申请号：US16635320

申请日：2018-08-01

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark Robert Bray ,  Jacqueline M. Mason ,  Tak W. Mak ,  Graham Fletcher

IPC: A61K31/519 ,  A61P35/00 ,  A61K39/395

CPC classification number: A61K31/519 ,  A61K39/3955 ,  A61P35/00

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：US20200230144A1

公开(公告)日：2020-07-23

申请号：US16635320

申请日：2018-08-01

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark Robert Bray ,  Jacqueline M. Mason ,  Tak W. Mak ,  Graham Fletcher

IPC: A61K31/519 ,  A61K39/395 ,  A61P35/00

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：US12109215B2

公开(公告)日：2024-10-08

申请号：US16644633

申请日：2018-09-07

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Jacqueline M. Mason ,  Mark R. Bray ,  Tak Wah Mak ,  Graham Fletcher

IPC: A61K31/5377 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/5377 ,  A61K39/3955 ,  A61P35/00

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：US20230165871A1

公开(公告)日：2023-06-01

申请号：US17917027

申请日：2021-04-05

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Graham Fletcher ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: A61K31/5377 ,  C07K16/28 ,  A61K45/06

CPC classification number: A61K31/5377 ,  A61K45/06 ,  C07K16/2827

Abstract: Provided herein are methods of treating triple negative breast cancer using an effective amount of Compound (I) represented by the formula: or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Uses of an effective amount of Compound [I] and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-linhibitor or a PD-L1 inhibitor for treating triple negative breast cancer are also provided herein.

公开(公告)号：US10239881B2

公开(公告)日：2019-03-26

申请号：US15521895

申请日：2015-10-09

Applicant: University Health Network

Inventor： Radoslaw Laufer ,  Grace Ng ,  Richard Brokx ,  Heinz W. Pauls ,  Sze-wan Li ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P37/06 ,  A61P29/00 ,  A61P35/00

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

公开(公告)号：US09402828B2

公开(公告)日：2016-08-02

申请号：US14592968

申请日：2015-01-09

Applicant: University Health Network

Inventor： Guohua Pan ,  Jacqueline M. Mason ,  Xin Wei ,  Miklos Feher

IPC: A61K31/553 ,  A61K31/00 ,  A61K31/535 ,  C07D273/00 ,  C07D211/00 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist.

Abstract translation: 本文提供了用于治疗癌症患者的方法和组合物，其中癌症的特征在于PTEN基因突变和/或PI3K基因突变。 在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物。

公开(公告)号：US20250049787A1

公开(公告)日：2025-02-13

申请号：US18723094

申请日：2022-12-21

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark R. Bray ,  Jacqueline M. Mason ,  Xin Wei ,  Gordon Duncan

IPC: A61K31/496 ,  A61K31/635 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma by administration of Compound (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230390294A1

公开(公告)日：2023-12-07

申请号：US18235679

申请日：2023-08-18

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark Robert Bray ,  Jacqueline M. Mason ,  Tak Wah Mak ,  Graham Fletcher

IPC: A61K31/519 ,  A61P35/00 ,  A61K39/395

CPC classification number: A61K31/519 ,  A61P35/00 ,  A61K39/3955

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：US20180282335A1

公开(公告)日：2018-10-04

申请号：US15521895

申请日：2015-10-09

Applicant: University Health Network

Inventor： Radoslaw Laufer ,  Grace Ng ,  Richard Brokx ,  Heinz W. Pauls ,  Sze-wan Li ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: C07D487/04 ,  A61P35/00 ,  A61P29/00 ,  A61P37/06

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

公开(公告)号：US09555042B2

公开(公告)日：2017-01-31

申请号：US15029269

申请日：2014-10-03

Applicant: University Health Network

Inventor： David W. Hedley ,  Ines Lohse ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: A61K31/5377 ,  A61K31/416 ,  A61P35/00 ,  C07D413/14 ,  A61K45/06 ,  A61K31/7068 ,  A61K33/24

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及通过施用结构式（I）表示的化合物或其药学上可接受的盐来治疗患有胰腺癌的受试者的方法。